RAC

0.00%

$1.69 race oncology ltd

Good post, my man. What I would say is that the clinical history...

First 58 Last

Share
Profile

Follow
Mason14

1,250 Posts.

12361

01/08/24

15:49

Post #: 75029750
Share

Originally posted by EDTD: ↑

I can only assume ASX11's point is that the other stock may be 'delisted' before that 12 month window for RAC is up. Hopefully, as I am a small holder from the 2 bucks days.

The only difficulty is, if you believe the other stock's prospects, it might be 2-3 times what it is now before delisting. (Maybe 4? I'm starting to get confused how 'platformy' the other stock is with this Alpha stuff in the works).

RAC's upside is more murky. I agree with others that $450 is pipe dream territory... but even the $30 chestnut everyone reckons is too low is 14 times from here. However whether that amount of upside is competing on the same 12 month timeline, I'm less sure.

I guess there is an argument that CPACS data ought to start rolling in assuming ethics/enrolment goes off without a hitch in the the next 6 months or so and we should in theory start getting healthy interest looking at how other stocks respond to such events. But the other stock has overcome inertia, we still need to get the snowball rolling from a somewhat standing start (ok, not completely, Dr T cornerstoned at 10c or whatever but we're still smallish market cap wise.)

As an aside I intensely get the sh*ts with some of the foam at the mouth "sell it all and buy RAC" posts that pop up from time to time. Find it grossly irresponsible. Even if you've got high hopes for RAC as many of us do, I find that sort of rabid up-ramping perversely switches on a bright orange caution light in my head despite my reading of announcements, Dr T's comms, research and the measured thoughts of other posters here. I am glad I'm not a new investor as while I likely would have still bought it would give me pause and I think it does this forum, and particularly beginner investors no favours.

Expand

Good post, my man.

What I would say is that the clinical history for Bisantrene easily warrants a $2B AUD MC.

You do not have to look far to see peers were sold for significantly more with considerably less.

I think you would struggle to find another opportunity as large, derisked, and undervalued on the ASX.

RAC Price at posting: $1.57 Sentiment: Buy Disclosure: Held
38 Upvote

0 Great analysis

Reply

Top Stories

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 24 more messages in this thread...

First 58 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.69		Change 0.000(0.00%)		Mkt cap ! $288.0M

Open	High	Low	Value	Volume
$1.66	$1.69	$1.57	$387.6K	237.1K

Buyers (Bids)

No.	Vol.	Price($)
1	807	$1.63

Sellers (Offers)

Price($)	Vol.	No.
$1.69	2376	1

View Market Depth

No.	Vol.	Price($)
1	807	1.630
1	4000	1.600
2	2300	1.580
1	636	1.570
1	6000	1.560

Price($)	Vol.	No.
1.690	2376	1
1.735	3313	1
1.750	2000	1
1.790	1000	1
1.800	2000	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

RAC (ASX) Chart

Good post, my man. What I would say is that the clinical history...

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Good post, my man. What I would say is that the clinical history...

Top Stories

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News